Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, First-in-human, Open-label Dose Escalation and Cohort Expansion Study of KB-0742 in Patients with Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma

Next Previous
X
Search
Trial Profile

Phase 1, First-in-human, Open-label Dose Escalation and Cohort Expansion Study of KB-0742 in Patients with Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Istisociclib (Primary)
  • Indications Adenoid cystic carcinoma; Carcinoma; Chordoma; Clear cell sarcoma; Diffuse large B cell lymphoma; Ewing's sarcoma; Liposarcoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Rhabdomyosarcoma; Sarcoma; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Kronos Bio

    • Most Recent Events

    • 04 Sep 2024 According to a Kronos Bio media release, the company will present a poster on Preclinical and clinical data support clinical expansion of KB-0742 at the American Association for Cancer Research (AACR) on Saturday, September 21, 2024
    • 08 Aug 2024 According to a Kronos Bio media release, first patient with platinum-resistant high-grade serous ovarian cancer cohort was enrolled and dosed in July. Data is expected in first half of 2025.
    • 23 Jul 2024 According to a Kronos Bio media release, the first patient dosed in an expansion cohort with KB-0742 at a dose of 80mg given on a four-days-on, three-days-off schedule.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top